RunUp Energy – Regulated Catalyst Framework | Merlintrader trading Blog

Merlintrader trading Blog – RunUp Energy

RunUp Energy – Regulated Catalyst Framework

Applying the RunUp logic to regulated utilities: small and mid-cap water and gas names whose value depends heavily on formal rate cases, cost-of-capital decisions and long-dated state-driven approvals.

Prices and metrics are indicative snapshots as of December 19, 2025 (or the latest available date on public sources) and may change quickly. Price-tracking lines inside each card show the move into December 29, 2025.

Regulated utilities Energy catalysts Rate cases Tariff reviews

Pillar 1

Water & gas rate-case calendar

Pillar 2

Cost-of-capital cycles (CPUC, ACC, OPUC)

Pillar 3

M&A and platform transitions

Timeframe

6–36 months, not 6 days

The core idea is identical to biotech RunUp: find a future regulatory decision or structured event, understand how material it is for the company, then observe how the market prices expectations as that window approaches. Here the “FDA calendar” becomes a map of state commissions, dockets and strategic milestones for utilities rather than drug trials.

RunUp Energy – concept and scope

In biotech, RunUp trading focuses on well-defined events like PDUFA dates or clinical read-outs, where a single decision can shift the value of a small company dramatically. In regulated utilities, the shape of the catalyst is different, but the underlying logic is surprisingly similar: a rate case, a cost-of-capital ruling or a large infrastructure approval can re-price the equity of a small or mid-cap water or gas utility over a period of months, sometimes years.

The key difference is speed. Biotech can move in hours around an FDA decision. Utilities usually move in slow motion: discovery, hearings, recommended orders, final orders, implementation of new tariffs and follow-on riders. The RunUp Energy framework does not try to make this “fast”; it tries to make it visible and organised, so that a trader or investor can look at a name and immediately answer three questions: what is the next real regulatory choke point, when is it likely to land, and how concentrated is the company’s earnings exposure to that decision.

Instead of one giant biotech-style catalyst calendar, we build a narrow lane of events for each utility: a sequence of dockets (ACC, BPU, CPUC, OPUC, etc.), settlement milestones, cost-of-capital resets and, for some platforms, strategic transitions (large acquisitions, asset sales, deleveraging plans). The objective is not to guess the outcome of each case but to map the window of attention during which the market tends to care most.

In practice, RunUp Energy is a way to translate classic “event-driven” thinking into the world of regulated utilities: fundamentals, balance sheet and valuation still matter, but they are read through the lens of forthcoming decisions by commissions and regulators rather than just quarterly EPS beats.

Focus on small and mid caps where a single rate case, cost-of-capital reset or acquisition can materially change earnings power.
Use only official regulatory calendars and company filings when dates exist; otherwise, mark windows explicitly as estimates based on historical cycles and prior dockets.
Keep risk, fundamentals and sentiment in the same view, avoiding “catalyst in vacuum” thinking where the rate case is analysed without context on leverage, ownership or valuation.
Accept that most utility catalysts are multi-step: the real story is often the path from filing to implementation, not a single binary headline.

RunUp Energy watchlist – first 9 regulated candidates

Each card below represents one potential RunUp Energy candidate. Risk labels (High/Medium/Low) are qualitative, based on size, balance sheet, exposure to single regions/cases and ownership structure. The analyst bands (base/bull/bear) are simple ranges around the current consensus target and are not trading signals.

GWRS ($8.47 → ~$8.51, +0.5% vs 19 Dec 2025)

Global Water Resources Inc

Regulated water – Arizona (ACC)

Water utility Risk: High

Arizona-based regulated water and wastewater utility with multiple active and recent rate cases at the ACC.
General rate case for GW–Santa Cruz and GW–Palo Verde filed March 2025, with hearings in December 2025 and a final ACC decision expected in the first half of 2026.
Small market cap, high insider ownership and premium valuation make the stock particularly sensitive to regulatory outcomes.

Catalyst window (RunUp Energy):
Primary: ACC Recommended Opinion & Order + Commission vote on Santa Cruz / Palo Verde rate case – expected H1 2026 based on company and ACC timelines.
Secondary: implementation of new tariffs in 2026–2027 and any follow-on DSIC/infrastructure-related riders.

Key fundamentals (Finviz snapshot):
Market Cap: ≈243–246M | P/E: 52.3 | Forward P/E: ~38 | PEG: ~4.6
P/S: 4.4 | P/B: 2.7 | Dividend: ~3.5% | Sales Q/Q: +8.4%
Insider Own: ~52.6% | Inst Own: ~30.4% | Short Float: ~1.6%
Analyst Recom: 1.00 | Target Price: 12.53 | 52W Range: 8.28 – 12.32

Price track (Dec 19 → Dec 29, 2025, approx.):
$8.47 → ~$8.51 (≈ +0.5%).

MSEX ($52.67 → ~$51.72, −1.8% vs 19 Dec 2025)

Middlesex Water Co

Regulated water – New Jersey / Delaware

Water utility Risk: Medium

Regulated water utility operating in New Jersey and Delaware with a history of steady, regulated growth.
2025 New Jersey BPU base rate case (Docket WR25060372) seeks a material increase in annual revenue; tariffs are currently under suspension.
Strong institutional ownership and moderate short interest; equity reaction is mostly tied to BPU decisions and long-term DSIC mechanics.

Catalyst window (RunUp Energy):
Primary: NJ BPU final order on the 2025 base rate case – current suspension extended to April 1, 2026, implying a decision window in late Q1–early Q2 2026 unless a further suspension is issued.
Secondary: DSIC and follow-on tariff adjustments over 2026–2027 that will phase in the full economic impact of the case.

Key fundamentals (Finviz snapshot):
Market Cap: ≈966M | P/E: 22.1 | Forward P/E: ~20.0 | PEG: ~3.8
P/S: 4.96 | P/B: 2.00 | Dividend: ~2.6% | Sales Q/Q: –1.8%
Insider Own: ~4.3% | Inst Own: ~79.4% | Short Float: ~3.6%
Analyst Recom: 2.50 | Target Price: 57.75 | 52W Range: 44.17 – 67.09

Price track (Dec 19 → Dec 29, 2025, approx.):
$52.67 → ~$51.72 (≈ −1.8%).

HTO ($49.40 → ~$48.70, −1.4% vs 19 Dec 2025)

H2O America

Multi-state regulated water – US

Water platform Risk: Medium

National water platform aggregating multiple regulated utilities across the US.
Very active on M&A: major Quadvest acquisition in Texas and additional wastewater systems expanding footprint.
ROE and cost-of-capital cycles in California have been formally deferred to 2027, giving medium-term visibility but also pushing the next big “reset” further out.

Catalyst window (RunUp Energy):
Primary: regulatory approvals and closing of the Quadvest acquisition in Texas – company has indicated a closing target by mid-2026 (1H 2026).
Secondary: cost-of-capital filings for San Jose Water and peer utilities now deferred to May 1, 2027, with decisions likely in late 2027–early 2028.

Key fundamentals (Finviz snapshot):
Market Cap: ≈1.77B | P/E: 15.7 | Forward P/E: ~16.0 | PEG: ~6.3
P/S: 2.20 | P/B: 1.16 | Dividend: ~3.4% | Sales Q/Q: 6.9%
Insider Own: ~7.8% | Inst Own: ~81.8% | Short Float: ~2.9%
Analyst Recom: 1.50 | Target Price: 62.00 | 52W Range: 43.75 – 57.17

Price track (Dec 19 → Dec 29, 2025, approx.):
$49.40 → ~$48.70 (≈ −1.4%).

OGS ($78.04 → ~$77.90, −0.2% vs 19 Dec 2025)

ONE Gas Inc

Regulated gas – TX / OK / KS

Gas utility Risk: Medium

Pure-play regulated gas distributor across Texas, Oklahoma and Kansas.
Texas Gas Service 2025 Statement of Intent triggers approvals in dozens of municipalities plus the Railroad Commission of Texas.
Short interest is relatively high for a utility, adding volatility around regulatory headlines.

Catalyst window (RunUp Energy):
Primary: Texas Gas Service SoI – city-level decisions and RRC order – most of the heavy lifting should land in Q1–Q2 2026 given filing in mid-2025 and standard Texas timelines.
Secondary: 2026 guidance updates and subsequent Texas/Oklahoma/Kansas filings that reflect the new allowed revenue, over 2026–2027.

Key fundamentals (Finviz snapshot):
Market Cap: ≈4.68B | P/E: ~18.2 | Forward P/E: ~16.6 | PEG: ~2.1
P/S: 1.98 | P/B: 1.47 | Dividend: ~3.4% | Sales Q/Q: 11.4%
Insider Own: ~1.3% | Inst Own: ~94.7% | Short Float: ~7.9%
Analyst Recom: 2.25 | Target Price: 84.86 | 52W Range: 66.38 – 83.96

Price track (Dec 19 → Dec 29, 2025, approx.):
$78.04 → ~$77.90 (≈ −0.2%).

CWT ($44.17 → ~$43.44, −1.7% vs 19 Dec 2025)

California Water Service Group

Regulated water – California & other states

Water utility Risk: Medium

Major regulated water utility with Cal Water as its flagship CPUC-regulated subsidiary.
Current GRC covers the 2025–2027 period; CPUC has approved deferral of the next cost-of-capital filing to May 1, 2027.
EPS has been under pressure, but long-term growth in rate base and acquisitions underpins the analyst bullishness.

Catalyst window (RunUp Energy):
Primary: full implementation of the 2025–2027 California GRC, including step-up rates and follow-up adjustments – drift catalyst across 2025–2027.
Secondary: next cost-of-capital cycle, with application on May 1, 2027 and CPUC decision likely in late 2027–early 2028.

Key fundamentals (Finviz snapshot):
Market Cap: ≈2.63B | P/E: ~19.0 | Forward P/E: ~17.6 | P/S: ~2.6 | P/B: ~1.6
Dividend: ≈2.7–2.8% | Sales Q/Q: 3.9%
Insider Own: ~0.7% | Inst Own: ~87.1% | Short Float: ~2.5%
Analyst Recom: 1.33 | Target Price: 53.67 | 52W Range: 41.29 – 51.63

Price track (Dec 19 → Dec 29, 2025, approx.):
$44.17 → ~$43.44 (≈ −1.7%).

AWR ($73.96 → ~$73.07, −1.2% vs 19 Dec 2025)

American States Water Co

Regulated water – California

Water utility Risk: Low

Stable California-focused water and electric utility with long dividend history and solid growth profile.
Golden State Water’s cost-of-capital filing has been officially deferred to May 1, 2027, locking in existing returns until then.
Catalysts are mainly the next CPUC cost-of-capital and GRC cycle, plus incremental infrastructure investments.

Catalyst window (RunUp Energy):
Primary: Golden State Water cost-of-capital filing on May 1, 2027 and subsequent CPUC decision – most likely in late 2027–first half 2028.
Secondary: smaller CPUC approvals on infrastructure projects and local rate adjustments across 2025–2027.

Key fundamentals (Finviz snapshot):
Market Cap: ≈2.86B | P/E: ~21.7 | Forward P/E: ~21.2 | PEG: ~3.7
P/S: 4.50 | P/B: 2.84 | Dividend: ~2.6% | Sales Q/Q: 12.9%
Insider Own: ~0.9% | Inst Own: ~82.7% | Short Float: ~2.1%
Analyst Recom: 2.00 | Target Price: 90.00 | 52W Range: 69.45 – 82.94

Price track (Dec 19 → Dec 29, 2025, approx.):
$73.96 → ~$73.07 (≈ −1.2%).

NWN ($47.04 → ~$47.14, +0.2% vs 19 Dec 2025)

Northwest Natural Holding Co

Regulated gas – Oregon & Pacific Northwest

Gas utility Risk: Medium

Gas and water utility with a strong footprint in Oregon and the broader Pacific Northwest.
Recent OPUC rate decisions and GET (Gas Earnings Threshold) benchmarks set the regulatory reference for 2024–2025.
Future full GRC cycles are likely to follow a 3–4 year pattern, making 2027–2028 a logical next window even if not yet on docket.

Catalyst window (RunUp Energy):
Primary (estimated): next full Oregon general rate case for gas operations – based on past cycles, a reasonable planning window is 2027–2028 (this is an inference, not an announced date).
Secondary: annual adjustments via GET mechanisms, tariff riders and advice letters over 2025–2027, which can still move earnings and sentiment modestly.

Key fundamentals (Finviz snapshot):
Market Cap: ≈1.95B | P/E: ~18.7 | Forward P/E: ~15.6 | PEG: ~1.4
P/S: 1.54 | P/B: 1.36 | Dividend: ~4.2% | Sales Q/Q: 20.3%
Insider Own: ~0.9% | Inst Own: ~79.7% | Short Float: ~2.6%
Analyst Recom: 1.50 | Target Price: 51.67 | 52W Range: 38.03 – 49.63

Price track (Dec 19 → Dec 29, 2025, approx.):
$47.04 → ~$47.14 (≈ +0.2%).

XEL ($73.61 → ~$74.34, +1.0% vs 19 Dec 2025)

Xcel Energy, Inc

Regulated electric – multi-state, USA

Large utility Risk: Low

Large regulated electric and gas utility operating in multiple US states, with overlapping general rate cases.
Minnesota electric rate case includes a detailed public calendar with hearings and a fixed deadline for the final MPUC order.
High institutional ownership makes it more of a sector benchmark; still useful for RunUp logic on the regulatory timetable.

Catalyst window (RunUp Energy):
Primary: Minnesota electric rate case – evidentiary hearings in December 2025, ALJ recommendation by April 30, 2026 and final MPUC order due by July 31, 2026 (official calendar).
Secondary: additional GRCs and fuel-cost adjustments in other states over 2026–2027, which shift earnings mix and capex recovery.

Key fundamentals (Finviz snapshot):
Market Cap: ≈43.5B | P/E: ~22.4 | Forward P/E: ~17.9 | PEG: ~2.0
P/S: 3.06 | P/B: 2.06 | Dividend: ~3.1% | Sales Q/Q: 7.5%
Insider Own: ~0.2% | Inst Own: ~92.6% | Short Float: ~5.5%
Analyst Recom: 1.62 | Target Price: 88.44 | 52W Range: 62.58 – 83.01

Price track (Dec 19 → Dec 29, 2025, approx.):
$73.61 → ~$74.34 (≈ +1.0%).

AQN ($5.86 → ~$6.29, +7.3% vs 19 Dec 2025)

Algonquin Power & Utilities Corp

Diversified utilities – Canada / North America

Hybrid regulated / renewables Risk: Medium

Diversified utility with both regulated operations and renewable power assets in North America.
Company is in the middle of a multi-year transition away from merchant renewables toward a more regulated earnings base.
RunUp logic here is more “strategic”: less about one single rate case, more about the completion of the deleveraging and the reset of the risk profile.

Catalyst window (RunUp Energy):
Primary: completion of the business transition toward a predominantly regulated utility model and delivery against the 2025–2027 financial framework – a broad strategic window, not a single binary event.
Secondary: individual rate decisions and settlements across Algonquin’s regulated subsidiaries over 2025–2027 (US and Canadian regulators), which should be read together as part of the transition rather than as isolated catalysts.

Key fundamentals (Finviz snapshot):
Market Cap: ≈4.6–5.0B | P/E: n/a (EPS TTM negative) | Forward P/E: ~16–17
P/S: ~2.0 | P/B: ~1.0–1.1 | Dividend: ~4.1–4.4% | Sales Q/Q: ~1.3%
Insider Own: ~3.0% | Inst Own: ~69% | Short Float: ~1.0%
Analyst Recom: ~2.5–2.6 | Target Price: ≈ 6.6–6.7 | 52W Range: 4.19 – 6.48

Price track (Dec 19 → Dec 29, 2025, approx.):
$5.86 → ~$6.29 (≈ +7.3%).

Rate-case calendar – first draft

This block summarises the key regulatory windows for the current RunUp Energy pool. For some names there are clear official deadlines; for others, especially where only a cycle is visible and no docket has been filed yet, the window is an estimate derived from history and should be treated as such.

As of December 29, 2025 there have been no final regulatory rulings that materially change the timelines described below. Most of the movement over the last ten days has been in prices, not in the calendar.

GWRS (ACC – Arizona): Santa Cruz / Palo Verde general rate case – ALJ recommendation and ACC final order expected across H1 2026, with tariff implementation flowing through 2026–2027.
MSEX (NJBPU – New Jersey): 2025 base rate case – tariffs suspended no later than April 1, 2026, implying a decision window between late Q1 and early Q2 2026.
HTO (CPUC + Texas): Texas Quadvest acquisition approvals targeted by mid-2026; San Jose Water cost-of-capital filing deferred to May 1, 2027 with decisions likely later in 2027.
OGS (Texas Gas Service – RRC + cities): 2025 SoI filing – the bulk of municipal and RRC decisions should fall between late 2025 and 1H 2026, with earnings impact progressively visible in 2026 guidance and beyond.
CWT (CPUC – Cal Water): 2025–2027 GRC already in place; next cost-of-capital cycle starts on May 1, 2027, with a decision likely in late 2027 or early 2028.
AWR (CPUC – Golden State Water): ROE and capital structure locked until the end of 2027; next cost-of-capital filing on May 1, 2027, decision window again late 2027–1H 2028.
NWN (OPUC – Oregon): recent rate decisions and GET benchmarks set the stage for the next full GRC cycle; based on historical cadence, an indicative window for a new large case would be 2027–2028 (to be confirmed when a docket is actually filed).
XEL (MPUC – Minnesota electric): Minnesota electric rate case with evidentiary hearings in December 2025; ALJ to issue recommendation by April 30, 2026, final MPUC order due by July 31, 2026.
AQN (multi-state, multi-regulator): no single PDUFA-style date; the relevant “window” is the whole strategic transition period 2025–2027, with quarterly milestones (earnings, settlements) as the company rebalances toward regulated earnings.

All of the above is informational, not operational advice. The purpose is to line up time horizons and regulatory choke points; any real decision should be based on independent research, direct reading of filings and, where appropriate, professional guidance.

How to use RunUp Energy in practice – three mini case studies

The goal is not to “guess the number” for every commission decision, but to have a simple playbook: pick a name, build a timeline from filing to implementation, and decide where you want (or do not want) to be exposed. Below are three quick examples on how the same framework can be read in different situations.

1) GWRS – classic small-cap rate-case RunUp

Setup: small Arizona water utility, high insider ownership, premium multiples, ACC general rate case in Santa Cruz / Palo Verde.
T–18 to T–12 months: filing and early discovery. Story is mostly ignored outside specialists; price often tracks sector with modest idiosyncratic drift.
T–9 to T–3 months: hearings, testimony, settlement negotiations. For many event-driven traders, this is where the “RunUp window” starts to matter: positioning on expectations of allowed ROE and revenue uplift vs current earnings base.
T–2 months to decision: draft/recommended orders and commission agendas appear. Volatility tends to increase; weak hands who never read the docket usually react late here.
Post-decision: if the order is broadly in line with expectations, the short-term “catalyst premium” can fade; the interesting part becomes the medium-term drift as new tariffs flow through and DSIC/infrastructure riders are implemented.

2) XEL – timing the benchmark instead of the outlier

Setup: large multi-state electric & gas utility, heavy institutional ownership, Minnesota electric rate case with hard calendar (hearings, ALJ recommendation, final MPUC order).
Early phase: for many readers, XEL is not a pure “trade idea” but a timing anchor: its Minnesota calendar helps frame the regulatory mood (earnings pressure, political signals, allowed ROEs) across comparable names.
Practical use: instead of trading XEL directly, a RunUp Energy user might monitor: (a) how the stock behaves between hearings and ALJ recommendation, and (b) how the sector reacts around the final order date, using that context when deciding what risk to take in smaller water/gas names that face similar issues a few quarters later.
Post-order: XEL behaviour after the order (relief rally vs disappointment) becomes a reference point when the market starts to pre-position for the next cost-of-capital cycle at CPUC or other commissions.

3) AQN – strategic RunUp instead of single-date RunUp

Setup: diversified utility in full transition from merchant renewables to a more regulated profile, with leverage concerns and a multi-year clean-up plan.
Time axis: here the “catalyst” is not one docket but the 2025–2027 sequence of disposals, tariff settlements, guidance updates and balance-sheet repair.
RunUp logic: the question becomes: “Is the market under-pricing the probability that AQN will emerge as a boring, mostly regulated utility with a re-based dividend and more predictable cash flows?”
Practical mapping: instead of marking a single date, a RunUp Energy tracker for AQN would:
- Log every material asset sale or regulatory step that de-risks the story.
- Compare the pace of deleveraging with the company’s stated plan.
- Watch valuation vs peers as the percentage of regulated earnings rises.
Outcome lens: if the transition stays on track, the “RunUp” is a slow re-rating over several years rather than a spike around a single commission vote.

These examples are intentionally generic and do not imply any view on what to do with the stocks mentioned. They are here to show how to read the timeline, not how to act on it. Any real decision should rest on your own homework, risk tolerance and, when appropriate, professional advice.

Merlintrader trading Blog – RunUp Energy

RunUp Energy – Framework per catalyst regolati

Applicare la logica RunUp alle utility regolamentate: small e mid cap dell’acqua e del gas la cui valutazione dipende in modo decisivo da rate case formali, decisioni sul costo del capitale e approvazioni pubbliche a lunga scadenza.

Prezzi e metriche sono istantanee indicative aggiornate al 19 dicembre 2025 (o all’ultimo dato disponibile su fonti pubbliche) e possono cambiare rapidamente. Le righe di “andamento prezzo” dentro le schede mostrano lo spostamento fino al 29 dicembre 2025.

Utility regolamentate Energy catalyst Rate case Revisioni tariffarie

Pilastro 1

Calendario rate case acqua e gas

Pilastro 2

Cicli di cost-of-capital (CPUC, ACC, OPUC)

Pilastro 3

M&A e transizioni di piattaforma

Orizzonte

6–36 mesi, non 6 giorni

L’idea di base è la stessa del RunUp biotech: individuare una decisione regolatoria futura o un evento strutturato, capire quanto è materiale per la società, e osservare come il mercato prezza le attese man mano che la finestra si avvicina. Qui il “calendario FDA” diventa una mappa di commissioni statali, docket e tappe strategiche per le utility, invece che di studi clinici.

RunUp Energy – concetto e campo di applicazione

Nel biotech, il RunUp classico si concentra su eventi ben definiti come le PDUFA o le letture di dati clinici, dove un’unica decisione può spostare il valore di una small cap in modo violento. Nelle utility regolamentate la forma del catalyst è diversa, ma la logica di fondo è sorprendentemente simile: un rate case, una decisione sul costo del capitale o una grande approvazione infrastrutturale possono riprezzare l’equity di una small o mid-cap dell’acqua o del gas nell’arco di mesi, a volte anni.

La grande differenza è la velocità. Nel biotech il movimento spesso si concentra in poche ore attorno alla decisione FDA. Nelle utility il film è rallentato: fasi di discovery, udienze, raccomandazioni del giudice amministrativo, delibera finale della commissione, implementazione delle nuove tariffe, eventuali meccanismi di claw-back o di indicizzazione. Il framework RunUp Energy non prova a rendere questo film “veloce”; prova a renderlo leggibile e strutturato, in modo che chi guarda un titolo possa rispondere subito a tre domande: qual è il prossimo vero punto di strozzatura regolatorio, quando è ragionevole aspettarselo, e quanto è concentrata l’esposizione degli utili su quella decisione.

Invece di un unico grande calendario stile biotech, costruiamo una corsia di eventi per ogni utility: una sequenza di docket (ACC, BPU, CPUC, OPUC, ecc.), tappe di settlement, reset di cost-of-capital e, per alcune piattaforme, transizioni strategiche (acquisizioni importanti, cessioni di asset, piani di deleveraging). L’obiettivo non è indovinare l’esito di ogni caso, ma mappare la finestra di attenzione in cui il mercato tende a concentrarsi sul titolo.

In pratica, RunUp Energy è un modo per portare il pensiero “event driven” nel mondo delle utility regolamentate: fondamentali, leva e valutazioni contano, ma vengono letti attraverso le decisioni future dei regolatori invece che solo attraverso gli EPS trimestrali.

Focus su small e mid cap in cui un singolo rate case, un reset di cost-of-capital o una grande acquisizione possono cambiare in modo visibile la capacità di generare utili.
Uso solo di calendari regolatori e documenti societari ufficiali quando le date esistono; negli altri casi finestre indicate esplicitamente come stime basate su cicli storici e docket precedenti.
Rischio, fondamentali e sentiment nella stessa vista, evitando di analizzare il catalyst “nel vuoto” senza considerare leva, ownership e valutazione.
Accettare che la maggior parte dei catalyst utility siano multi-step: spesso la storia vera è il percorso da filing a implementazione, non un unico titolo di agenzia.

RunUp Energy watchlist – prime 9 utility regolamentate

Ogni scheda qui sotto rappresenta un potenziale candidato RunUp Energy. I label di rischio (High/Medium/Low) sono qualitativi e riflettono dimensione, struttura finanziaria, concentrazione geografica/regolatoria e struttura proprietaria. Le bande di scenario base/bull/bear sono semplici intervalli intorno al target consenso e non vanno lette come segnali operativi.

GWRS ($8.47 → ~$8.51, +0.5% vs 19 dic 2025)

Global Water Resources Inc

Water regolata – Arizona (ACC)

Water utility Rischio: High

Utility regolata acqua e wastewater con base in Arizona e più rate case attivi o recenti presso l’ACC.
General rate case per i sistemi Santa Cruz e Palo Verde presentato a marzo 2025, udienze a dicembre 2025 e decisione finale attesa nel primo semestre 2026.
Small cap con forte insider ownership e valutazione premium: il titolo è molto sensibile agli esiti regolatori.

Finestra catalyst (RunUp Energy):
Primaria: Recommended Opinion & Order + voto finale dell’ACC sul rate case Santa Cruz / Palo Verde – attesa in H1 2026 sulla base delle tempistiche comunicate da società e commissione.
Secondaria: implementazione delle nuove tariffe nel periodo 2026–2027 e possibili rider legati agli investimenti infrastrutturali.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈243–246M | P/E: 52,3 | Forward P/E: ~38 | PEG: ~4,6
P/S: 4,4 | P/B: 2,7 | Dividend: ~3,5% | Sales Q/Q: +8,4%
Insider Own: ~52,6% | Inst Own: ~30,4% | Short Float: ~1,6%
Analyst Recom: 1,00 | Target Price: 12,53 | 52W Range: 8,28 – 12,32

Andamento prezzo (19 dic → 29 dic 2025, circa):
$8,47 → ~$8,51 (≈ +0,5%).

MSEX ($52.67 → ~$51.72, −1.8% vs 19 dic 2025)

Middlesex Water Co

Water regolata – New Jersey / Delaware

Water utility Rischio: Medium

Utility dell’acqua regolata operante in New Jersey e Delaware con storia di crescita regolata abbastanza lineare.
Base rate case 2025 presso la NJ BPU (Docket WR25060372) con richiesta di aumento rilevante dei ricavi annui; tariffe attualmente sospese.
Ownership istituzionale elevata e short interest moderato; la reazione del titolo è legata soprattutto alle decisioni BPU e alla dinamica DSIC.

Finestra catalyst (RunUp Energy):
Primaria: ordine finale NJ BPU sul base rate case 2025 – sospensione estesa fino al 1 aprile 2026, che implica una finestra decisionale tra fine Q1 e inizio Q2 2026 salvo ulteriori proroghe.
Secondaria: aggiustamenti DSIC e altre variazioni tariffarie nel periodo 2026–2027 che completano l’impatto economico del caso.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈966M | P/E: 22,1 | Forward P/E: ~20,0 | PEG: ~3,8
P/S: 4,96 | P/B: 2,00 | Dividend: ~2,6% | Sales Q/Q: –1,8%
Insider Own: ~4,3% | Inst Own: ~79,4% | Short Float: ~3,6%
Analyst Recom: 2,50 | Target Price: 57,75 | 52W Range: 44,17 – 67,09

Andamento prezzo (19 dic → 29 dic 2025, circa):
$52,67 → ~$51,72 (≈ −1,8%).

HTO ($49.40 → ~$48.70, −1.4% vs 19 dic 2025)

H2O America

Piattaforma water regolata – USA multi-stato

Water platform Rischio: Medium

Piattaforma nazionale che aggrega diverse utility dell’acqua regolamentate in più stati USA.
Molto attiva su M&A: acquisizione importante di Quadvest in Texas e altre operazioni wastewater che ampliano il perimetro.
Cicli di ROE e cost-of-capital in California formalmente rinviati al 2027, con visibilità di medio termine ma “reset” posticipato.

Finestra catalyst (RunUp Energy):
Primaria: approvazioni regolatorie e closing dell’acquisizione Quadvest in Texas – la società indica come obiettivo mid-2026 (1H 2026).
Secondaria: filing di cost-of-capital per San Jose Water e operatori comparabili rinviati al 1 maggio 2027, con decisioni verosimili tra fine 2027 e inizio 2028.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈1,77B | P/E: 15,7 | Forward P/E: ~16,0 | PEG: ~6,3
P/S: 2,20 | P/B: 1,16 | Dividend: ~3,4% | Sales Q/Q: 6,9%
Insider Own: ~7,8% | Inst Own: ~81,8% | Short Float: ~2,9%
Analyst Recom: 1,50 | Target Price: 62,00 | 52W Range: 43,75 – 57,17

Andamento prezzo (19 dic → 29 dic 2025, circa):
$49,40 → ~$48,70 (≈ −1,4%).

OGS ($78.04 → ~$77.90, −0.2% vs 19 dic 2025)

ONE Gas Inc

Gas regolato – Texas / Oklahoma / Kansas

Gas utility Rischio: Medium

Pure-play gas distribution regolata in Texas, Oklahoma e Kansas.
La Statement of Intent 2025 per Texas Gas Service attiva un percorso di approvazioni in decine di municipalità più la Railroad Commission of Texas.
Short interest relativamente alto per una utility, con volatilità aggiuntiva intorno alle notizie regolatorie.

Finestra catalyst (RunUp Energy):
Primaria: SoI Texas Gas Service – decisioni a livello cittadino e ordine della RRC – gran parte dell’impatto dovrebbe cadere in Q1–Q2 2026 dato il filing mid-2025 e le tempistiche tipiche del Texas.
Secondaria: aggiornamenti di guidance 2026 e ulteriori filing in Texas/Oklahoma/Kansas che riflettono i nuovi ricavi ammessi nel periodo 2026–2027.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈4,68B | P/E: ~18,2 | Forward P/E: ~16,6 | PEG: ~2,1
P/S: 1,98 | P/B: 1,47 | Dividend: ~3,4% | Sales Q/Q: 11,4%
Insider Own: ~1,3% | Inst Own: ~94,7% | Short Float: ~7,9%
Analyst Recom: 2,25 | Target Price: 84,86 | 52W Range: 66,38 – 83,96

Andamento prezzo (19 dic → 29 dic 2025, circa):
$78,04 → ~$77,90 (≈ −0,2%).

CWT ($44.17 → ~$43.44, −1.7% vs 19 dic 2025)

California Water Service Group

Water regolata – California e altri stati

Water utility Rischio: Medium

Grande utility dell’acqua regolata, con Cal Water come principale controllata soggetta a CPUC.
La GRC 2025–2027 è già in vigore; la CPUC ha approvato il rinvio del prossimo ciclo cost-of-capital al 1 maggio 2027.
EPS sotto pressione negli ultimi anni, ma crescita del rate base e M&A sostengono il case di lungo periodo visto dagli analisti.

Finestra catalyst (RunUp Energy):
Primaria: piena implementazione della GRC 2025–2027 in California, inclusi step-up tariffari e aggiustamenti successivi – catalyst di “drift” lungo 2025–2027.
Secondaria: prossimo ciclo di cost-of-capital, con filing al 1 maggio 2027 e decisione CPUC verosimilmente a fine 2027 / inizio 2028.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈2,63B | P/E: ~19,0 | Forward P/E: ~17,6 | P/S: ~2,6 | P/B: ~1,6
Dividend: ≈2,7–2,8% | Sales Q/Q: 3,9%
Insider Own: ~0,7% | Inst Own: ~87,1% | Short Float: ~2,5%
Analyst Recom: 1,33 | Target Price: 53,67 | 52W Range: 41,29 – 51,63

Andamento prezzo (19 dic → 29 dic 2025, circa):
$44,17 → ~$43,44 (≈ −1,7%).

AWR ($73.96 → ~$73.07, −1.2% vs 19 dic 2025)

American States Water Co

Water regolata – California

Water utility Rischio: Low

Utility dell’acqua ed elettrica focalizzata sulla California, con lunga storia di dividendi e crescita del rate base.
La cost-of-capital per Golden State Water è stata ufficialmente rinviata al 1 maggio 2027, bloccando il ritorno regolato fino a quella data.
I catalyst principali sono il prossimo ciclo CPUC (cost-of-capital + GRC) e gli investimenti infrastrutturali progressivi.

Finestra catalyst (RunUp Energy):
Primaria: filing cost-of-capital per Golden State Water al 1 maggio 2027 e decisione CPUC nel periodo fine 2027 – prima metà 2028.
Secondaria: approvazioni CPUC su progetti infrastrutturali e aggiustamenti locali nel periodo 2025–2027.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈2,86B | P/E: ~21,7 | Forward P/E: ~21,2 | PEG: ~3,7
P/S: 4,50 | P/B: 2,84 | Dividend: ~2,6% | Sales Q/Q: 12,9%
Insider Own: ~0,9% | Inst Own: ~82,7% | Short Float: ~2,1%
Analyst Recom: 2,00 | Target Price: 90,00 | 52W Range: 69,45 – 82,94

Andamento prezzo (19 dic → 29 dic 2025, circa):
$73,96 → ~$73,07 (≈ −1,2%).

NWN ($47.04 → ~$47.14, +0.2% vs 19 dic 2025)

Northwest Natural Holding Co

Gas regolato – Oregon & Pacific Northwest

Gas utility Rischio: Medium

Utility gas e water con forte presenza in Oregon e nel Pacifico Nord-Ovest.
Recenti decisioni OPUC e benchmark GET (Gas Earnings Threshold) fissano la base regolatoria per il 2024–2025.
I futuri cicli di GRC probabilmente seguiranno un pattern 3–4 anni, rendendo 2027–2028 una finestra plausibile anche se non ancora formalizzata.

Finestra catalyst (RunUp Energy):
Primaria (stimata): prossimo general rate case completo per le attività gas in Oregon – sulla base dei cicli passati, finestra ragionevole 2027–2028 (stima, non data ufficiale).
Secondaria: aggiustamenti annuali via meccanismi GET, rider tariffari e advice letter nel periodo 2025–2027, che possono comunque muovere utili e sentiment.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈1,95B | P/E: ~18,7 | Forward P/E: ~15,6 | PEG: ~1,4
P/S: 1,54 | P/B: 1,36 | Dividend: ~4,2% | Sales Q/Q: 20,3%
Insider Own: ~0,9% | Inst Own: ~79,7% | Short Float: ~2,6%
Analyst Recom: 1,50 | Target Price: 51,67 | 52W Range: 38,03 – 49,63

Andamento prezzo (19 dic → 29 dic 2025, circa):
$47,04 → ~$47,14 (≈ +0,2%).

XEL ($73.61 → ~$74.34, +1.0% vs 19 dic 2025)

Xcel Energy, Inc

Elettrica regolata – USA multi-stato

Large utility Rischio: Low

Grande utility elettrica e gas regolata attiva in più stati USA, con diversi general rate case in parallelo.
La rate case elettrica in Minnesota ha un calendario pubblico dettagliato, con udienze e scadenza fissa per l’ordine finale della MPUC.
Ownership istituzionale molto elevata: XEL è più un benchmark di settore, ma resta utile per leggere il timing regolatorio in logica RunUp.

Finestra catalyst (RunUp Energy):
Primaria: rate case elettrica Minnesota – udienze di merito a dicembre 2025, raccomandazione ALJ entro il 30 aprile 2026 e ordine finale MPUC entro il 31 luglio 2026 (calendario ufficiale).
Secondaria: ulteriori GRC e aggiustamenti fuel-cost in altri stati nel periodo 2026–2027, che spostano mix utili e recupero capex.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈43,5B | P/E: ~22,4 | Forward P/E: ~17,9 | PEG: ~2,0
P/S: 3,06 | P/B: 2,06 | Dividend: ~3,1% | Sales Q/Q: 7,5%
Insider Own: ~0,2% | Inst Own: ~92,6% | Short Float: ~5,5%
Analyst Recom: 1,62 | Target Price: 88,44 | 52W Range: 62,58 – 83,01

Andamento prezzo (19 dic → 29 dic 2025, circa):
$73,61 → ~$74,34 (≈ +1,0%).

AQN ($5.86 → ~$6.29, +7.3% vs 19 dic 2025)

Algonquin Power & Utilities Corp

Utility diversificata – Canada / Nord America

Hybrid regulated / renewables Rischio: Medium

Utility diversificata con attività sia regolamentate sia rinnovabili merchant in Nord America.
Società in piena transizione multi-year verso un profilo di utili più regolato e meno esposto al merchant.
La logica RunUp qui è più “strategica”: meno centrata su un singolo rate case, più sul completamento del deleveraging e sul reset del profilo rischio/rendimento.

Finestra catalyst (RunUp Energy):
Primaria: completamento della transizione verso un modello prevalentemente regolato e delivery rispetto al framework finanziario 2025–2027 – finestra strategica ampia, non evento binario singolo.
Secondaria: decisioni tariffarie e settlement delle controllate regolamentate in USA e Canada nel periodo 2025–2027, da leggere in aggregato come parte della transizione più che come PDUFA isolate.

Fundamentali chiave (snapshot Finviz):
Market Cap: ≈4,6–5,0B | P/E: n/d (EPS TTM negativo) | Forward P/E: ~16–17
P/S: ~2,0 | P/B: ~1,0–1,1 | Dividend: ~4,1–4,4% | Sales Q/Q: ~1,3%
Insider Own: ~3,0% | Inst Own: ~69% | Short Float: ~1,0%
Analyst Recom: ~2,5–2,6 | Target Price: ≈ 6,6–6,7 | 52W Range: 4,19 – 6,48

Andamento prezzo (19 dic → 29 dic 2025, circa):
$5,86 → ~$6,29 (≈ +7,3%).

Calendario delle rate case – prima bozza

Questo blocco riassume le principali finestre regolatorie per il pool attuale RunUp Energy. Per alcuni titoli esistono scadenze ufficiali chiare; per altri, in cui si vede solo il ciclo ma non c’è ancora un docket depositato, la finestra è una stima derivata dalla storia e va letta come tale.

Al 29 dicembre 2025 non risultano decisioni regolatorie finali che modifichino in modo sostanziale le timeline descritte. Negli ultimi giorni i cambiamenti sono stati soprattutto sui livelli di prezzo, non sul calendario.

GWRS (ACC – Arizona): general rate case Santa Cruz / Palo Verde – raccomandazione ALJ e ordine finale ACC attesi in H1 2026, con implementazione tariffaria che si protrae nel 2026–2027.
MSEX (NJBPU – New Jersey): base rate case 2025 – tariffe sospese non oltre il 1 aprile 2026, che implica finestra decisionale tra fine Q1 e inizio Q2 2026.
HTO (CPUC + Texas): approvazioni per l’acquisizione Quadvest in Texas con obiettivo mid-2026; filing cost-of-capital per San Jose Water rinviato al 1 maggio 2027, decisioni probabili nel corso del 2027.
OGS (Texas Gas Service – RRC + città): SoI 2025 – la maggior parte delle decisioni municipali e della RRC cade tra fine 2025 e prima metà 2026, con riflessi sugli utili visibili nelle guidance 2026 e successive.
CWT (CPUC – Cal Water): GRC 2025–2027 già in vigore; prossimo ciclo cost-of-capital dal 1 maggio 2027, con decisione attesa tra fine 2027 e inizio 2028.
AWR (CPUC – Golden State Water): ROE e struttura del capitale bloccate fino a fine 2027; filing cost-of-capital il 1 maggio 2027, finestra decisionale ancora una volta fine 2027 – prima metà 2028.
NWN (OPUC – Oregon): recenti decisioni e benchmark GET preparano il terreno per il prossimo general rate case; sulla base del ritmo storico, la finestra indicativa per un nuovo grande caso è 2027–2028 (in attesa di docket formale).
XEL (MPUC – Minnesota elettrica): rate case elettrica con udienze a dicembre 2025; raccomandazione ALJ entro il 30 aprile 2026 e ordine finale MPUC entro il 31 luglio 2026.
AQN (multi-stato, multi-regolatore): nessuna data singola stile PDUFA; la finestra rilevante è l’intero periodo di transizione strategica 2025–2027, con milestone trimestrali (earnings, settlement) man mano che il business si sposta verso utili più regolati.

Tutto quanto sopra ha finalità puramente informative. Lo scopo è allineare orizzonti temporali e punti di strozzatura regolatori; qualsiasi decisione concreta richiede ricerca autonoma, lettura diretta dei documenti ufficiali e, dove necessario, il supporto di un professionista abilitato.

Come usare RunUp Energy in pratica – tre mini case study

L’obiettivo non è “indovinare il numero” di ogni decisione della commissione, ma avere una piccola regia: scegliere un titolo, costruire la timeline da filing a implementazione, e decidere dove vuoi (o non vuoi) essere esposto. Sotto ci sono tre esempi rapidi di come lo stesso framework si legge in situazioni diverse.

1) GWRS – il RunUp classico da small cap su rate case

Setup: piccola utility acqua in Arizona, insider ownership elevata, multipli rich, general rate case ACC su Santa Cruz / Palo Verde.
T–18 a T–12 mesi: filing e prime fasi di discovery. La storia è seguita quasi solo dagli specialisti; il prezzo tende a muoversi col settore, con un po’ di drift idiosincratico.
T–9 a T–3 mesi: udienze, testimonianze, trattative di settlement. Per molti event-driven questa è la vera “RunUp window”: ci si posiziona sulle attese di ROE ammesso e aumento ricavi rispetto alla base utili attuale.
T–2 mesi alla decisione: compaiono draft o recommended order e le date di agenda della commissione. La volatilità aumenta; chi non ha mai letto il docket tende a reagire tardi qui.
Post-decisione: se l’ordine è allineato alle attese, il “premio catalyst” di breve può rientrare; diventa interessante la deriva di medio termine mentre le nuove tariffe entrano a regime e si aggiungono i rider sugli investimenti.

2) XEL – usare il benchmark invece dell’outlier

Setup: grande utility elettrica e gas multi-stato, forte presenza istituzionale, rate case elettrica Minnesota con calendario rigido (udienze, raccomandazione ALJ, ordine finale MPUC).
Fase iniziale: per molti lettori XEL non è “l’idea di trade” ma l’ancora: il suo calendario Minnesota aiuta a leggere il clima regolatorio (pressione sugli utili, segnali politici, ROE ammessi) sulle comparabili.
Uso pratico: invece di tradare XEL direttamente, un utente RunUp Energy può osservare:
- come si comporta il titolo tra udienze e raccomandazione ALJ;
- come reagisce il settore intorno alla data dell’ordine finale;
e usare quel contesto quando decide quanto rischio prendersi su small/mid-cap acqua/gas che affronteranno temi simili qualche trimestre dopo.
Dopo l’ordine: il comportamento di XEL (relief rally o delusione) diventa un riferimento quando il mercato inizia a pre-posizionarsi per il prossimo ciclo di cost-of-capital alla CPUC o presso altre commissioni.

3) AQN – RunUp strategico invece che da singola data

Setup: utility diversificata in piena transizione da rinnovabili merchant a profilo più regolato, con temi di leva e piano di pulizia pluriennale.
Asse temporale: qui il “catalyst” non è un singolo docket ma la sequenza 2025–2027 di cessioni, settlement tariffari, aggiornamenti di guidance e riduzione del debito.
Logica RunUp: la domanda vera è: “Il mercato sta sottovalutando la probabilità che AQN esca dalla transizione come utility perlopiù regolata, più noiosa ma con flussi di cassa più prevedibili?”
Mappatura pratica: invece di segnare una data sola, un tracker RunUp Energy su AQN:
- registra ogni vendita di asset o passo regolatorio che riduce il rischio;
- confronta il ritmo di deleveraging col piano dichiarato;
- osserva la valutazione vs peer man mano che sale la quota di utili regolati.
Lente di lettura: se la transizione resta on track, il “RunUp” è una lenta rivalutazione su più anni più che un picco attorno a un singolo voto di commissione.

Anche questi esempi sono volutamente generici e non implicano alcuna indicazione su cosa fare con i titoli citati. Servono a mostrare come leggere la timeline, non come agire. Qualsiasi decisione concreta deve poggiare sul tuo lavoro di analisi, sulla tua tolleranza al rischio e, quando serve, su consulenza professionale.

Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Authors: Merlintrader, Jane and Gemini

Author’s note (English)

In every report I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this report as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

AI usage disclosure (English)

This report has been prepared using a human + AI workflow. Drafting, editing and data organisation are supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Legal disclaimer (English) – please read carefully

This report is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in this document should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in this report, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this document is not investment advice and should not be used as such.

I testi completi dei disclaimer e delle condizioni d’uso, in versione sia italiana che inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicated here sotto.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Tools and research platforms used in this report

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
Seeking Alpha – institutional-grade news flow, transcripts and fundamental data; useful for SEC filings, estimates and conference call details.
Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

Some of the links above are affiliate links. If you decide to subscribe or purchase through them, it may generate a small commission for Merlintrader at no extra cost to you. This helps keep the site online and the reports freely accessible. You are under no obligation to use these links; always choose the solution that best fits your needs and your own evaluation.

Full legal information, risk warnings and terms of use (in both Italian and English) are available on the official Merlintrader legal pages:

Italian version: Disclaimer e avvertenze sui rischi | Condizioni d’uso e informativa sulla privacy

The same pages also include the corresponding English text or an English equivalent of the main legal notices, so that international readers can access the core risk disclosures and terms of use.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

Authors: Merlintrader, Jane and Gemini

Nota dell’autore (Italiano)

In ogni report condivido ciò che vedo e come lo interpreto personalmente, partendo dai dati grezzi di documenti ufficiali, comunicazioni delle società, trascrizioni delle call e altre fonti primarie quando disponibili. Alcune parti del lavoro di ricerca e di impaginazione sono supportate da assistenti IA (Jane e Gemini), che mi aiutano a organizzare i dati, verificare i dettagli e migliorare grafici o elementi visivi. Le valutazioni finali, le opinioni e le conclusioni restano comunque esclusivamente mie, da trader come te, non da consulente finanziario abilitato o analista iscritto ad albi professionali. Il sentiment di mercato può cambiare molto rapidamente, mentre i documenti ufficiali e i numeri restano quelli che sono. È anche possibile che commetta errori: raccogliere e confrontare tempistiche FDA, dati clinici, filing e aggiornamenti societari è un lavoro complesso, quindi qualche imprecisione può sfuggire. Se noti qualcosa che non ti torna, segnalamelo e lo correggerò. Non considerare questo report come consulenza personalizzata, ma come materiale informativo da confrontare con le tue ricerche e con il parere di professionisti qualificati.

Informativa sull’uso di IA generativa (Italiano)

Questo report è stato redatto utilizzando un flusso di lavoro combinato umano + IA. La stesura, la revisione e l’organizzazione dei dati sono supportate da strumenti di intelligenza artificiale generativa, ad esempio modelli linguistici di grandi dimensioni forniti da terze parti, sulla base di istruzioni e controlli definiti dall’autore. Le fonti utilizzate sono pubbliche e la selezione finale delle informazioni, le verifiche, le opinioni e le conclusioni restano sotto la responsabilità esclusiva dell’autore.

Disclaimer legale (Italiano) – leggere con attenzione

Questo report ha finalità esclusivamente informative e didattiche. Non costituisce in alcun modo consulenza in materia di investimenti, ricerca in materia di investimenti in senso regolamentare, gestione di portafogli, né raccomandazione personalizzata o generica ad acquistare, vendere o detenere strumenti finanziari. L’autore non è un consulente finanziario abilitato all’esercizio della professione, non è un promotore finanziario, non è un analista iscritto ad albi professionali e non svolge servizi di investimento ai sensi della normativa vigente.

Qualsiasi riferimento a scenari possibili, livelli di prezzo, probabilità o catalyst ha valore puramente illustrativo e riflette una valutazione personale e non professionale basata su informazioni pubbliche disponibili al momento della stesura. Nulla di quanto scritto rappresenta sollecitazione al pubblico risparmio, offerta al pubblico di prodotti finanziari o promessa di rendimento o di protezione del capitale. In particolare, i titoli biotech e healthcare possono essere estremamente volatili e speculativi, soprattutto in prossimità di eventi clinici o regolatori (PDUFA, letture di trial, ecc.).

L’autore può detenere, o aver detenuto, posizioni long o short su alcuni degli strumenti finanziari menzionati nel report e può aprire, chiudere o modificare tali posizioni senza preavviso. Questa possibile coincidenza di interessi può influenzare il taglio o l’attenzione dell’analisi. La presenza di eventuali posizioni personali non trasforma in alcun modo questo documento in consulenza finanziaria e non deve essere interpretata come tale.

Prima di assumere qualsiasi decisione di investimento o di trading, è indispensabile effettuare le proprie analisi e valutazioni e, se necessario, rivolgersi a un consulente finanziario indipendente e abilitato, in grado di considerare la tua situazione personale, gli obiettivi e la propensione al rischio. Le informazioni riportate possono contenere errori, omissioni o non essere aggiornate; né l’autore né Merlintrader possono essere ritenuti responsabili per eventuali perdite, dirette o indirette, derivanti dall’utilizzo di questo contenuto.

I testi completi dei disclaimer e delle condizioni d’uso, in versione sia italiana che inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicate qui sotto.

Tools and research platforms used in this report

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
Seeking Alpha – institutional-grade news flow, transcripts and fundamental data; useful for SEC filings, estimates and conference call details.
Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

Full legal information, risk warnings and terms of use (in both Italian and English) are available on the official Merlintrader legal pages:

Italian version: Disclaimer e avvertenze sui rischi | Condizioni d’uso e informativa sulla privacy

The same pages also include the corresponding English text or an English equivalent of the main legal notices, so that international readers can access the core risk disclosures and terms of use.

Biotech Catalyst Calendar

Open the Biotech Catalyst Calendar

RunUp Energy – concept and scope

RunUp Energy watchlist – first 9 regulated candidates

Rate-case calendar – first draft

How to use RunUp Energy in practice – three mini case studies

1) GWRS – classic small-cap rate-case RunUp

2) XEL – timing the benchmark instead of the outlier

3) AQN – strategic RunUp instead of single-date RunUp

RunUp Energy – concetto e campo di applicazione

RunUp Energy watchlist – prime 9 utility regolamentate

Calendario delle rate case – prima bozza

Come usare RunUp Energy in pratica – tre mini case study

1) GWRS – il RunUp classico da small cap su rate case

2) XEL – usare il benchmark invece dell’outlier

3) AQN – RunUp strategico invece che da singola data

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

One platform. All your brokers.

Author’s note (English)

AI usage disclosure (English)

Legal disclaimer (English) – please read carefully

Tools and research platforms used in this report

Biotech Catalyst Calendar

Nota dell’autore (Italiano)

Informativa sull’uso di IA generativa (Italiano)

Disclaimer legale (Italiano) – leggere con attenzione

Tools and research platforms used in this report

Biotech Catalyst Calendar

Trending now